These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25529192)

  • 1. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
    Rodón J; Carducci M; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly A; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
    Invest New Drugs; 2015 Apr; 33(2):357-70. PubMed ID: 25529192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.
    Rodon J; Carducci MA; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly AL; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
    Clin Cancer Res; 2015 Feb; 21(3):553-60. PubMed ID: 25424852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
    Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
    Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
    Fujiwara Y; Nokihara H; Yamada Y; Yamamoto N; Sunami K; Utsumi H; Asou H; TakahashI O; Ogasawara K; Gueorguieva I; Tamura T
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1143-52. PubMed ID: 26526984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
    Capper D; von Deimling A; Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Estrem ST; Lahn MM; Wick W
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
    Liu X; Yu M; Chen Y; Zhang J
    Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.
    Kovacs RJ; Maldonado G; Azaro A; Fernández MS; Romero FL; Sepulveda-Sánchez JM; Corretti M; Carducci M; Dolan M; Gueorguieva I; Cleverly AL; Pillay NS; Baselga J; Lahn MM
    Cardiovasc Toxicol; 2015 Oct; 15(4):309-23. PubMed ID: 25488804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.
    Maier A; Peille AL; Vuaroqueaux V; Lahn M
    Cell Oncol (Dordr); 2015 Apr; 38(2):131-44. PubMed ID: 25573078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
    Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Capper D; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Lahn MM; Wick W
    Neuro Oncol; 2016 Aug; 18(8):1146-56. PubMed ID: 26902851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
    Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
    Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
    Wick A; Desjardins A; Suarez C; Forsyth P; Gueorguieva I; Burkholder T; Cleverly AL; Estrem ST; Wang S; Lahn MM; Guba SC; Capper D; Rodon J
    Invest New Drugs; 2020 Oct; 38(5):1570-1579. PubMed ID: 32140889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Kelley RK; Gane E; Assenat E; Siebler J; Galle PR; Merle P; Hourmand IO; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Faivre S; Benhadji KA; Giannelli G
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00056. PubMed ID: 31295152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disposition and metabolism of [
    Cassidy KC; Gueorguieva I; Miles C; Rehmel J; Yi P; Ehlhardt WJ
    Xenobiotica; 2018 Apr; 48(4):382-399. PubMed ID: 28436712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
    Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
    Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.
    Honda K; Yamamoto N; Nokihara H; Tamura Y; Asahina H; Yamada Y; Suzuki S; Yamazaki N; Ogita Y; Tamura T
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):577-84. PubMed ID: 23860959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extracellular miRNA-21 as a novel biomarker in glioma: Evidence from meta-analysis, clinical validation and experimental investigations.
    Qu K; Lin T; Pang Q; Liu T; Wang Z; Tai M; Meng F; Zhang J; Wan Y; Mao P; Dong X; Liu C; Niu W; Dong S
    Oncotarget; 2016 Jun; 7(23):33994-4010. PubMed ID: 27166186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer.
    Ajay Kumar TV; Athavan AAS; Loganathan C; Saravanan K; Kabilan S; Parthasarathy V
    Comput Biol Chem; 2018 Oct; 76():232-244. PubMed ID: 30077902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
    Ikeda M; Morimoto M; Tajimi M; Inoue K; Benhadji KA; Lahn MMF; Sakai D
    Invest New Drugs; 2019 Feb; 37(1):118-126. PubMed ID: 29995286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC.
    Cao Y; Agarwal R; Dituri F; Lupo L; Trerotoli P; Mancarella S; Winter P; Giannelli G
    Cell Death Dis; 2017 Feb; 8(2):e2634. PubMed ID: 28230858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
    Dituri F; Mazzocca A; Fernando J; Peidrò FJ; Papappicco P; Fabregat I; De Santis F; Paradiso A; Sabbà C; Giannelli G
    PLoS One; 2013; 8(6):e67109. PubMed ID: 23826206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.